Leerink Partnrs Forecasts Increased Earnings for Genmab A/S

Genmab A/S (NASDAQ:GMAB) – Research analysts at Leerink Partnrs boosted their FY2025 earnings per share (EPS) estimates for shares of Genmab A/S in a research note issued to investors on Thursday, May 8th. Leerink Partnrs analyst J. Chang now expects that the company will post earnings of $1.68 per share for the year, up from their prior forecast of $1.59. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.45 per share. Leerink Partnrs also issued estimates for Genmab A/S’s Q4 2025 earnings at $0.62 EPS and FY2026 earnings at $1.98 EPS.

GMAB has been the subject of a number of other reports. BNP Paribas raised Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 11th. Sanford C. Bernstein downgraded shares of Genmab A/S from a “market perform” rating to an “underperform” rating in a report on Tuesday, April 1st. Truist Financial reduced their target price on Genmab A/S from $50.00 to $45.00 and set a “buy” rating for the company in a report on Tuesday, March 11th. HC Wainwright reiterated a “buy” rating and issued a $37.00 price objective (down previously from $50.00) on shares of Genmab A/S in a research report on Wednesday, April 9th. Finally, Leerink Partners upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 target price for the company in a research report on Thursday, February 13th. One analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $39.17.

Genmab A/S Price Performance

Shares of GMAB stock opened at $19.31 on Monday. The company has a market cap of $12.38 billion, a P/E ratio of 11.10, a P/E/G ratio of 2.65 and a beta of 1.04. Genmab A/S has a one year low of $17.24 and a one year high of $30.41. The firm has a 50-day moving average of $19.90 and a 200-day moving average of $20.82.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.23 by $0.08. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. The business had revenue of $715.00 million during the quarter, compared to the consensus estimate of $5.17 billion.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC increased its holdings in shares of Genmab A/S by 96.6% in the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after purchasing an additional 1,051 shares during the last quarter. Crossmark Global Holdings Inc. raised its stake in shares of Genmab A/S by 8.8% in the fourth quarter. Crossmark Global Holdings Inc. now owns 41,622 shares of the company’s stock valued at $868,000 after acquiring an additional 3,377 shares during the period. SG Americas Securities LLC raised its position in Genmab A/S by 82.7% in the 4th quarter. SG Americas Securities LLC now owns 26,396 shares of the company’s stock worth $551,000 after purchasing an additional 11,949 shares during the period. Blue Trust Inc. lifted its stake in Genmab A/S by 33.4% in the fourth quarter. Blue Trust Inc. now owns 5,757 shares of the company’s stock worth $120,000 after purchasing an additional 1,442 shares during the last quarter. Finally, R Squared Ltd bought a new position in shares of Genmab A/S during the fourth quarter valued at approximately $93,000. 7.07% of the stock is owned by hedge funds and other institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.